Miltenyi Biotec

StraightFrom® Whole Blood REAlease® CD8 MicroBead Kit
human

Order no. 130-132-983

Contents

1. Description
   - 1.1 Principle of the REAlease MACS® Separation
   - 1.2 Background information
   - 1.3 Applications
   - 1.4 Reagent and instrument requirements
2. Protocol
   - 2.1 Protocol overview
   - 2.2 Sample preparation
   - 2.3 Magnetic labeling
   - 2.4 Manual magnetic separation with the MidiMACS™ Separator or QuadroMACS™ Separator
   - 2.5 (Optional) Removal of the REAlease Biotin Complex
3. Example of a separation using the StraightFrom Whole Blood REAlease CD8 MicroBead Kit

1. Description

This product is for research use only.

Components	**2 mL StraightFrom Whole Blood REAlease CD8-Biotin, human** **2×4 mL StraightFrom Whole Blood REAlease Anti-Biotin MicroBeads (CD8, human)** **4 mL REAlease Bead Release Reagent (50×)** **4 mL REAlease Release Reagent** **4 mL REAlease Stop Reagent**
Capacity	For max. 40 mL whole blood.
Product format	REAlease Stop Reagent is supplied in buffer containing 0.05% sodium azide. All other reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
Storage	Store protected from light at 2–8 °C. Do not freeze. The expiration date is indicated on the vial label.

1.1 Principle of the REAlease MACS Separation

The REAlease Technology relies on recombinantly engineered antibody fragments to label specific cell surface markers. The fragments are developed to have low affinity for epitopes. However, when fragments are multimerized as a REAlease Biotin Complex (i.e. REAlease CD8-Biotin) they bind to epitopes with high avidity. REAlease Technology can control the multimer/monomer state of antibody fragments. With this technology a controlled label release is possible where monomerized antibody fragments dissociate from the cell surface, enabling users to obtain bead- and label-free cells.

No sample preparation is required, including density gradient centrifugation or erythrocyte lysis. $CD8^+$ cells are labeled with StraightFrom Whole Blood REAlease CD8-Biotin (REAlease Biotin Complex). Subsequently, StraightFrom Whole Blood REAlease Anti-Biotin MicroBeads (CD8, human) bind to REAlease Biotin Complex. Then, the cell suspension is loaded onto a MACS Column, which is placed in the magnetic field of a MACS Separator. The magnetically labeled cells are retained within the column. The unlabeled non-target cells flow through; this cell fraction is thus depleted of $CD8^+$ T cells. Using the REAlease Bead Release Reagent, which removes the MicroBeads from the cell, target cells are eluted within the magnetic field. Finally, during the subsequent incubation with the REAlease Release Reagent, the REAlease Biotin Complex monomerizes and dissociates from the cell surface leaving the cells free of all labels.

1.3 Background information

StraightFrom Whole Blood REAlease CD8 MicroBead Kit has been developed for the positive selection of cells directly from whole blood. In human whole blood the CD8 antigen is expressed on cytotoxic T cells and on a subset of $CD16^+$ NK cells. The CD8 antigen acts as an accessory molecule in the recognition of MHC class I/peptide complexes by the TCR heterodimer on $CD8^+$ cytotoxic T cells. The StraightFrom Whole Blood REAlease CD8 MicroBead Kit, human is an indirect magnetic labeling system that allows to obtain cells free of MicroBeads and REAlease Biotin Complex.

1.4 Applications

- Isolation of $CD8^+$ cells from whole blood. The purified $CD8^+$ cells are well suited for further flow cytometric, functional, or molecular analysis.
- Isolation of $CD8^+$ cell subset that needs to be label-free.

Miltenyi Biotec B.V. & Co. KG
Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
Phone +49 2204 8306-0, Fax +49 2204 85197
macsde@miltenyi.com
www.miltenyibiotec.com

140-006-600.01

1.5 Reagent and instrument requirements


- Whole Blood Column Kit (# 130-093-545).
- Separation buffer: Prepare a solution containing phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2 mM EDTA by diluting MACS BSA Stock Solution (# 130-091-376) 1:20 with autoMACS® Rinsing Solution (# 130-091-222). Keep buffer cold (2–8 °C). Alternatively, use autoMACS Running Buffer. Degas buffer before use, as air bubbles could block the column.

  ▲ **Note:** EDTA can be replaced by other supplements such as anticoagulant citrate dextrose formula-A (ACD-A) or citrate phosphate dextrose (CPD). BSA can be replaced by other proteins such as human serum albumin, human serum, or fetal bovine serum (FBS). Buffers or media containing Ca^{2+} or Mg^{2+} are not recommended for use.
- REAlease Bead Release buffer: Prepare a 1:50 dilution of REAlease Bead Release Reagent (50×), e.g., for 50 mL add 1 mL of REAlease Bead Release Reagent to 49 mL of separation buffer.

  ▲ **Note:** Use freshly prepared buffer the same day. Store at room temperature.
- Manual separation:
  - MidiMACS Separator (# 130-042-302) or QuadroMACS Separator (# 130-090-976)
  - MACS Acrylic Tube Rack (# 130-041-406) or MACS 15 mL Tube Rack (# 130-091-052)
- (Optional) Fluorochrome-conjugated REAfinity™ Antibodies for flow cytometric analysis. For more information about antibodies refer to www.miltenyibiotec.com/antibodies.
- (Optional) Propidium Iodide Solution (# 130-093-233) or 7-AAD Staining Solution (# 130-111-568) for flow cytometric exclusion of dead cells.
- (Optional) Red Blood Cell Lysis Solution (10×) (# 130-094-183).

2. Protocol

2.1 Protocol overview



2.2 Sample preparation

▲ The StraightFrom Whole Blood REAlease MicroBead Kit has been developed for positive selection of target cells from whole blood samples of up to 40 mL.

▲ Anticoagulants such as EDTA, citrate dextrose formula-A (ACD-A) or citrate phosphate dextrose (CPD) can be used. For subsequent molecular biology applications use EDTA as an anticoagulant. Replacing EDTA can decrease purity and/or recovery.

1. Collect up to 15 mL of venous blood in a collection tube containing an appropriate anticoagulant.
2. Proceed to magnetic labeling (2.3).



2.3 Magnetic labeling

▲ The recommended incubation temperature is room temperature (19–25 °C).

▲ Volumes for magnetic labeling given below are for 1 mL of anticoagulated whole blood. When working with larger volumes, scale up all reagent volumes and total volumes accordingly (e.g. for 2 mL, use twice the volume of all indicated reagent volumes and total volumes). When working with volumes below 1 mL (minimal volume 0.25 mL), scale down all reagent and total volumes accordingly.

1. Add 50 µL of StraightFrom Whole Blood REAlease CD8-Biotin per 1 mL whole blood.
2. Mix well and incubate for 10 minutes at room temperature (19–25 °C).
3. Add 200 µL of StraightFrom Whole Blood REAlease Anti-Biotin MicroBeads (CD8, human) per 1 mL whole blood.
4. Mix well and incubate for 5 minutes at room temperature (19–25 °C).
5. Proceed to magnetic separation (2.4).



2.4 Manual magnetic separation with the MidiMACS Separator or QuadroMACS Separator

1. Place Whole Blood Column in the magnetic field of a MidiMACS Separator or QuadroMACS Separator. Insert Whole Blood Column with the column wings to the front into the separator.
2. Prepare column by rinsing with 3 mL separation buffer.
3. Apply magnetically labeled cell suspension onto the prepared Whole Blood Column. Collect flow-through containing unlabeled cells.

   ▲ **Note:** Add max. 12.5 mL labeled cells onto one Whole Blood Column.

   ▲ **Note:** The reservoir of the Whole Blood Column can contain a maximum of 7.5 mL. Samples greater than 7.5 mL should be applied in aliquots to the column.

4. Wash Whole Blood Column with 2×2 mL separation buffer. Collect unlabeled cells that pass through and combine with the flow-through from step 3.

   ▲ **Note:** Perform washing steps by adding buffer aliquots as soon as the column reservoir is empty.

   ▲ **Note:** Apply separation buffer to the edge of the column reservoir to wash out remaining whole blood.

5. Place a new collection tube under the Whole Blood Column.
6. Pipette 4×3.5 mL REAlease Bead Release Reagent (1:50) onto the Whole Blood Column.
7. Cells are now free from MicroBeads and ready for analysis or downstream applications.
8. (Optional) Remaining erythrocytes can be lysed using Red Blood Cell Lysis Solution (10×).
9. (Optional) Proceed to 2.5 Removal of REAlease Biotin Complex.

2.5 (Optional) Removal of the REAlease Biotin Complex

▲ The recommended incubation temperature is at room temperature (19–25 °C).

1. Centrifuge cell suspension at 300×g for 10 minutes. Aspirate supernatant completely.
2. Resuspend cell pellet in appropriate amount of separation buffer. For 1 mL of whole blood: 1 mL.
3. Add an appropriate amount of REAlease Release Reagent. For 1 mL of whole blood: 20 µL.
4. Mix well and incubate for 5 minutes.
5. Cells are now free from REAlease Biotin Complex and MicroBeads and are ready for analysis or downstream applications.
6. (Optional) For second magnetic labeling with REAlease MicroBeads or MACS Anti-Biotin MicroBeads, centrifuge cell suspension at 300×g for 10 minutes. Aspirate supernatant completely. Resuspend cell pellet in 1 mL of REAlease Stop Reagent and mix well. Then, proceed with magnetic labeling.

   ▲ **Note:** For best recovery and purity of cells, the amount of MACS MicroBeads for the second positive labeling may need optimization as the starting frequency of target cells may be different from a PBMC sample.

Unless otherwise specifically indicated, all Miltenyi Biotec products and services are for research use only and not for diagnostic or therapeutic use.


140-006-600.01

3. Example of a separation using the StraightFrom Whole Blood REAlease CD8 MicroBead Kit

CD8$^+$ cells were isolated from whole blood using the StraightFrom Whole Blood REAlease CD8 MicroBead Kit, human and Whole Blood Columns. Cells were fluorescently stained with the REAfinity Antibody CD8-FITC and analyzed by flow cytometry using the MACSQuant® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.


The CD8$^+$ T cell content of the isolated fraction is typically 98% ± 2 (mean ± SD).


A) Cell purity



B) Label-free cells: release of REAlease Biotin Complex

The efficient removal of all labels was shown by using Biotin Antibody-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD8$^+$ cells"), whereas the label-free CD8$^+$ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation.





Refer to **www.miltenyibiotec.com** for all data sheets and protocols. Miltenyi Biotec provides technical support worldwide. Visit www.miltenyibiotec.com for local Miltenyi Biotec Technical Support contact information.

Legal notices

Limited product warranty

Miltenyi Biotec B.V. & Co. KG and/or its affiliate(s) warrant this product to be free from material defects in workmanship and materials and to conform substantially with Miltenyi Biotec's published specifications for the product at the time of order, under normal use and conditions in accordance with its applicable documentation, for a period beginning on the date of delivery of the product by Miltenyi Biotec or its authorized distributor and ending on the expiration date of the product's applicable shelf life stated on the product label, packaging or documentation (as applicable) or, in the absence thereof, ONE (1) YEAR from date of delivery ("Product Warranty"). Miltenyi Biotec's Product Warranty is provided subject to the warranty terms as set forth in Miltenyi Biotec's General Terms and Conditions for the Sale of Products and Services available on Miltenyi Biotec's website at www.miltenyibiotec.com, as in effect at the time of order ("Product Warranty"). Additional terms may apply. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF A PRODUCT IS SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION METHODS.

Technical information

The technical information, data, protocols, and other statements provided by Miltenyi Biotec in this document are based on information, tests, or experience which Miltenyi Biotec believes to be reliable, but the accuracy or completeness of such information is not guaranteed. Such technical information and data are intended for persons with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. Miltenyi Biotec shall not be liable for any technical or editorial errors or omissions contained herein.

All information and specifications are subject to change without prior notice. Please contact Miltenyi Biotec Technical Support or visit www.miltenyibiotec.com for the most up-to-date information on Miltenyi Biotec products.

Licenses

This product and/or its use may be covered by one or more pending or issued patents and/or may have certain limitations. Certain uses may be excluded by separate terms and conditions. Please contact your local Miltenyi Biotec representative or visit Miltenyi Biotec's website at www.miltenyibiotec.com for more information.

The purchase of this product conveys to the customer the non-transferable right to use the purchased amount of the product in research conducted by the customer (whether the customer is an academic or for-profit entity). This product may not be further sold. Additional terms and conditions (including the terms of a Limited Use Label License) may apply.

CUSTOMER'S USE OF THIS PRODUCT MAY REQUIRE ADDITIONAL LICENSES DEPENDING ON THE SPECIFIC APPLICATION. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING FOR ITSELF WHETHER IT HAS ALL APPROPRIATE LICENSES IN PLACE. Miltenyi Biotec provides no warranty that customer's use of this product does not and will not infringe intellectual property rights owned by a third party. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

Trademarks

autoMACS, MACS, MACSQuant, MidiMACS, the Miltenyi Biotec logo, QuadroMACS, REAfinity, REAlease, and StraightFrom are registered trademarks or trademarks of Miltenyi Biotec B.V. & Co. KG and/or its affiliates in various countries worldwide.

Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.